Thus, the potent down-regulation of peripheral and also mucosal TNF-α and IL-10 secretion by Gal-4 underscores the potential therapeutic use of Gal-4 and explains its beneficial effect in experimental colitis. The gene discussed is LGALS4; the disease is colitis.